{"ticker": {"uuid": "59a9a1c8-ef0f-4cda-8509-656a373532e3", "symbol": "EDSA", "name": "Edesa Biotech Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "[EFFECT] Edesa Biotech, Inc. SEC Filing", "summary": "This article announces an EFFECT SEC filing for Edesa Biotech, Inc. (EDSA), indicating the effectiveness of an S-3 Shelf Registration Statement. The filing has a neutral impact and sentiment, and the notice of effectiveness specifies July 13, 2026, as the effective date. The arti", "url": "https://www.stocktitan.net/sec-filings/EDSA/effect-edesa-biotech-inc-sec-filing-dbec03d1d2d5.html", "source_name": "Stock Titan", "published_at": "2026-07-14T09:41:58", "published_display": "14 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) details $3.5M private placement and 729,241-share resale", "summary": "Edesa Biotech (EDSA) has registered 729,241 common shares for resale by existing investors who participated in a June 2026 private placement, raising approximately $3.5 million. The company itself will not receive any proceeds from these resales, as the original private placement", "url": "https://www.stocktitan.net/sec-filings/EDSA/424b3-edesa-biotech-inc-prospectus-filed-pursuant-to-rule-424-b-3-812a0759bd19.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:40:35", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "EDSA Stock Rallied Over 50% Today: What\u2019s Ahead For The Small-Cap Biotech?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOVVUyQnQ0RmZrdFVCUk9RYU55bUdHeURCVTR2ZjlmN1dfSkJvZi0tWkNyS3BZRWVmdU96RWRfd2R2V1NDV3JwamJKcy11aVQ5U1NnemhJTXJNRkdVcnVIZk8xdkhoblpXYVliZjIySWh6WjNFZGFTbjNtQy1qdXpWbXk1dGZKZlMtaUw5ZXNxdlVlbWdDdnpsWWFSbnFnUVhPcWV2d0Q2bUhscDlzUEtPV0JLdUNhV29QeEtQRTNkUFVnZ0g0SzU5RTg1amdHYmVoZW9DbQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T15:00:21+00:00", "published_display": "12 Jul 2026 15:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech(EDSA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxQeTJ3TUs5Rlh4UlBLTXBaWk9fTThqV2ZDZWVscV9rMEhGMElVZU04WVo0UU9PN0FOR001TV9RS0hMdlBMUGlnYS00R1JvdDhIUmVzOENlM2VTbVlKOUZRejdCTkNrQ01ISEF1UlI2LU5ibjRDeHFGWFJZcUlDelBrWjdTTlBqaXRwNEtYTHpjTWRkREFvZFI1eGREdWlNYXVReE9OZGRhWXcxeUg5SEd6bV93aFlPSmF5ODJZZTNieFZwc3RmWENMOUU5aHNfS3pGc3N3SkpwSXRienlTU0pxMC1yTGpJZ2Zfb21BMlVsVHNPYXNyLWdfZTBNOXVxMURSaEJDcFNHM1NPNHBmTWtUSlRiM0RmOXlJVk9RbjZvbHMwMGd0djF1VVNGVQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T05:07:53+00:00", "published_display": "08 Jul 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Edesa Biotech, Inc. \u2013 NASDAQ:EDSA", "summary": "This article focuses on the enterprise value to EBIT forward for Edesa Biotech, Inc. (NASDAQ: EDSA). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics and market performance.", "url": "https://www.tradingview.com/symbols/NASDAQ-EDSA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T09:11:10", "published_display": "06 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech | 4: Statement of changes in beneficial ownership of securities-Officer Nijhawan Pardeep", "summary": "This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Officer Nijhawan Pardeep at Edesa Biotech. It indicates a filing related to the beneficial ownership of securities, likely detailing transactions or holdings by the named officer.", "url": "https://www.moomoo.com/news/notice/306619730/edesa-biotech-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-05T01:09:30", "published_display": "05 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) CEO receives 3,378-share RSU grant", "summary": "Edesa Biotech's CEO, Pardeep Nijhawan, was granted 3,378 restricted share units (RSUs) which vested immediately under the company's 2019 Equity Incentive Compensation Plan. This grant increases his direct holdings to 888,062 common shares. The Form 4 filing also details his indir", "url": "https://www.stocktitan.net/sec-filings/EDSA/form-4-edesa-biotech-inc-insider-trading-activity-5eb05e4f930e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:30", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (NASDAQ: EDSA) registers 729,241 shares for resale", "summary": "Edesa Biotech Inc. (NASDAQ: EDSA) has filed an S-3 registration statement to allow for the resale of up to 729,241 common shares. These shares were issued in a recent private placement that closed on June 16, 2026, generating approximately $3.5 million for the company, but Edesa ", "url": "https://www.stocktitan.net/sec-filings/EDSA/s-3-edesa-biotech-inc-shelf-registration-statement-a4071fb6ecfb.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:30", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDSA: Positive Exploratory Data in Patients with AKI", "summary": "Edesa Biotech, Inc. (EDSA) announced positive exploratory data for its drug paridiprubart (EB05) in patients with acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS), showing a significant 32% relative reduction in 28-day mortality and a 23% relative reductio", "url": "https://scr.zacks.com/news/news-details/2026/EDSA-Positive-Exploratory-Data-in-Patients-with-AKI-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-07-02T16:40:30", "published_display": "02 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brookline Capital Initiates Edesa Biotech(EDSA.US) With Buy Rating, Announces Target Price $21", "summary": "Brookline Capital has initiated coverage on Edesa Biotech (EDSA.US) with a Buy rating. The firm has set a price target of $21 for Edesa Biotech's stock. This initiation and target price announcement suggest a positive outlook for the company from Brookline Capital.", "url": "https://www.moomoo.com/news/post/72210663/brookline-capital-initiates-edesa-biotech-edsaus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-29T21:40:17", "published_display": "29 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brookline initiates Edesa Biotech stock with buy on pipeline", "summary": "Brookline Capital Markets has initiated coverage on Edesa Biotech (NASDAQ: EDSA) with a buy rating and a price target of $21.00, citing the company's promising pipeline which includes EB06 for vitiligo and a Phase 3-ready asset, EB01, for allergic contact dermatitis. The firm als", "url": "https://www.investing.com/news/analyst-ratings/brookline-initiates-edesa-biotech-stock-with-buy-on-pipeline-93CH-4766205", "source_name": "Investing.com", "published_at": "2026-06-29T20:39:38", "published_display": "29 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech, Inc. Actuals & Estimates (NASDAQ:EDSA)", "summary": "This article provides an overview of Edesa Biotech, Inc. (EDSA) stock, including its current price, performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report date, and recent revenue and net income figures. The", "url": "https://www.tradingview.com/symbols/NASDAQ-EDSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:41:45", "published_display": "26 Jun 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Edesa Biotech, Inc. \u2013 NASDAQ:EDSA", "summary": "This page provides financial information for Edesa Biotech, Inc. (NASDAQ: EDSA), specifically focusing on its Price to Book Forward metric. The content indicates that the market was closed at the time of viewing, with no trades executed for the company. The page is from TradingVi", "url": "https://www.tradingview.com/symbols/NASDAQ-EDSA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:24", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Edesa Biotech, Inc. \u2013 NASDAQ:EDSA", "summary": "This article briefly mentions the \"Price to sales forward\" metric for Edesa Biotech, Inc. (NASDAQ: EDSA), indicating it's a financial data point available on TradingView. The page appears to be a financial overview or data display page for the company on the platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-EDSA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:39:48", "published_display": "25 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO, Company Secretary & Director of Edesa Biotech Pardeep Nijhawan Buys 28% More Shares", "summary": "Pardeep Nijhawan, CEO of Edesa Biotech, recently purchased US$800k worth of company stock at an average price of US$5.21, increasing his holding by 28%. This was the largest insider purchase in the last year, with insiders being net buyers overall despite making previous investme", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edsa/edesa-biotech/news/ceo-company-secretary-director-of-edesa-biotech-pardeep-nijh", "source_name": "Simply Wall Street", "published_at": "2026-06-19T12:09:13", "published_display": "19 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) joint filing reports 5.4% stake by Millennium group", "summary": "A Schedule 13G filing reveals that a group of related entities, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, collectively hold a 5.4% beneficial ownership in Edesa Biotech (EDSA). This stake, a", "url": "https://www.stocktitan.net/sec-filings/EDSA/schedule-13g-edesa-biotech-inc-passive-investment-disclosure-5-2150c1c98f1d.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:40:37", "published_display": "18 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Inc (EDSA) Institutional Confidence", "summary": "The article analyzes the institutional confidence in Edesa Biotech Inc (EDSA), noting a current shareholding score of 3.00, placing it 193rd out of 388 in its industry. Institutional shareholding proportion increased by 52.45% quarter-over-quarter to 49.07%. Steven Cohen is ident", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edsa/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:53", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Inc (EDSA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Edesa Biotech Inc (EDSA), detailing its current risk score, beta value, and various volatility metrics. The company ranks 233 out of 388 in the Biotechnology & Medical Research industry with a risk assessment score of 2.19. Key metrics ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edsa/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:53", "published_display": "18 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Edesa Biotech Inc (EDSA), highlighting its current earnings forecast score, average analyst price target of $9.00, and a \"Buy\" trend based on 2 analysts. It also details the company's recent and expected EPS performance and compares i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edsa/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:50", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Inc (EDSA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Edesa Biotech Inc.'s (EDSA) dividend history and stock splits. It notes that the company has not distributed any dividends in the past five years and details a 7-for-1 reverse merger stock split that occurred on October 10, 2023. The article a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edsa/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:50", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) CEO invests $799,995.50 in private share purchase", "summary": "Edesa Biotech's CEO, Pardeep Nijhawan, privately purchased 153,550 common shares at $5.21 each, totaling $799,995.50, increasing his direct holdings to 884,684 shares. This strategic investment, noted in a Form 4 SEC filing, signifies a significant commitment to the company. The ", "url": "https://www.stocktitan.net/sec-filings/EDSA/form-4-edesa-biotech-inc-insider-trading-activity-2333bb03c6d2.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:25", "published_display": "16 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nijhawan lifts Edesa Biotech (EDSA) beneficial ownership stake to 19.99%", "summary": "Dr. Pardeep Nijhawan has increased his beneficial ownership in Edesa Biotech, Inc. (EDSA) to 19.99% through various transactions including restricted stock unit grants, open-market purchases, and a private placement. This updated ownership of 2,210,022 common shares is detailed i", "url": "https://www.stocktitan.net/sec-filings/EDSA/schedule-13d-a-edesa-biotech-inc-amended-major-shareholder-report-0961c8bee2f4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:25", "published_display": "16 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did EDSA Stock Rally More Than 70% Today?", "summary": "Edesa Biotech's stock surged over 70% after reporting positive late-stage study results for its experimental drug, paridiprubart, which showed a statistically significant reduction in mortality for Acute Respiratory Distress Syndrome (ARDS) patients. The company is now pursuing r", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-edsa-stock-rally-today/cZRwIqaR4Cs", "source_name": "Stocktwits", "published_at": "2026-06-14T04:09:41", "published_display": "14 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech, Inc. Announces $3.5 Million PIPE Financing to Advance Clinical Programs", "summary": "Edesa Biotech, Inc. has secured approximately $3.5 million through a private investment in public equity (PIPE) financing. This funding, involving the sale of common shares to investors and the CEO, is intended to advance the company's vitiligo program, support its drug candidate", "url": "https://www.quiverquant.com/news/Edesa+Biotech,+Inc.+Announces+$3.5+Million+PIPE+Financing+to+Advance+Clinical+Programs", "source_name": "Quiver Quantitative", "published_at": "2026-06-12T20:41:45", "published_display": "12 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Raises $3.5 Million in Private Placement, Issues 729,241 Shares", "summary": "Edesa Biotech has successfully raised $3.5 million through a private placement, issuing 729,241 common shares to various investors including its CEO, with prices set at $4.69 and $5.21 respectively. The company also entered a Registration Rights Agreement, committing to file resa", "url": "https://www.tradingview.com/news/tradingview:1084aa11122ab:0-edesa-biotech-raises-3-5-million-in-private-placement-issues-729-241-shares/", "source_name": "TradingView", "published_at": "2026-06-11T13:39:43", "published_display": "11 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors", "summary": "Edesa Biotech, Inc. announced a private placement (PIPE) financing expected to generate approximately $3.5 million in gross proceeds. The investment, which includes participation from Edesa's CEO and healthcare-focused investors, will fund the advancement of the company\u2019s vitilig", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310539/0/en/edesa-biotech-announces-3-5-million-private-placement-of-common-shares-led-by-ceo-and-healthcare-focused-investors.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T13:39:43", "published_display": "11 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (Nasdaq: EDSA) sets $3.5M PIPE led by CEO", "summary": "Edesa Biotech has announced a private placement (PIPE) financing expected to raise approximately $3.5 million. The company will sell 729,241 common shares, with its CEO purchasing shares at a slightly higher price than other investors, demonstrating insider participation. Proceed", "url": "https://www.stocktitan.net/sec-filings/EDSA/8-k-edesa-biotech-inc-reports-material-event-66d415f42a04.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:43", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO backs $3.5M raise to advance Edesa vitiligo work", "summary": "Edesa Biotech has announced a $3.5 million private placement of common shares, led by its CEO and healthcare-focused investors. The proceeds will be used to advance the company's vitiligo program and its drug candidate paridiprubart, as well as for general corporate purposes. The", "url": "https://www.stocktitan.net/news/EDSA/edesa-biotech-announces-3-5-million-private-placement-of-common-lkm85qgw68zw.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:43", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech, Inc. announced that it expects to receive $3.42014 million in funding", "summary": "Edesa Biotech, Inc. is set to receive $3.42014 million in funding through a private placement of 729,241 common shares at $4.69 per share. The transaction, expected to close on June 15, 2026, includes participation from the company's CEO and healthcare-focused investors. This fun", "url": "https://www.marketscreener.com/news/edesa-biotech-inc-announced-that-it-expects-to-receive-3-42014-million-in-funding-ce7f5cd8de81f22c", "source_name": "www.marketscreener.com", "published_at": "2026-06-10T15:09:18", "published_display": "10 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/edesa-biotech-says-paridiprubart-linked-141240796.html", "source_name": "MT Newswires", "published_at": "2026-06-05T14:12:40+00:00", "published_display": "05 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/edesa-biotech-reports-positive-exploratory-132000030.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T13:20:00+00:00", "published_display": "05 Jun 2026 13:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Early trial data hint at fewer deaths from acute kidney injury", "summary": "Edesa Biotech (Nasdaq: EDSA) reported positive exploratory data for its drug paridiprubart in 101 hospitalized patients with acute kidney injury (AKI) and respiratory distress. The data, drawn from prior Phase 2/3 ARDS studies, suggested a 32% relative reduction in 28-day mortali", "url": "https://www.stocktitan.net/news/EDSA/edesa-biotech-reports-positive-exploratory-data-for-paridiprubart-in-h5u9vmajkinn.html", "source_name": "Stock Titan", "published_at": "2026-06-05T13:11:06", "published_display": "05 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploratory AKI data show lower mortality with paridiprubart at Edesa (NASDAQ: EDSA)", "summary": "Edesa Biotech (NASDAQ: EDSA) reported exploratory subgroup data indicating that its anti-TLR4 antibody, paridiprubart, may reduce mortality and major adverse kidney events (MAKE30) in critically ill patients with acute kidney injury (AKI) and respiratory distress. Pooled analyses", "url": "https://www.stocktitan.net/sec-filings/EDSA/8-k-edesa-biotech-inc-reports-material-event-28b8257eecb7.html", "source_name": "Stock Titan", "published_at": "2026-06-05T13:11:06", "published_display": "05 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/edesa-biotech-present-data-paridiprubart-131500125.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T13:15:00+00:00", "published_display": "19 May 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sirenia (EDSA) discloses 600,000-share, 7.2% stake in Edesa Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQklXT1g0WUdnRDNjZ29qd29tVENWQzZaOXRTeWRzLVdpQnMwVWtRN0VPak1aa18tb3lWUkN6Y0dxQ2J1UG9tbmJsTmhncC1kUmVRUXVOUGZUaTdrY0FRM2U1aER2QkVFMWQ0QWJZVmlGeDJHM0VBb0JXZFFUQmtxZHNfamZoOUFweFItazhEZ1lhM2tJaWxLMXl2MnE2b2t6WFotY0RpeFBJM2w2eDg1bTB6aEJVSUZsVEhZS3FYTEJOdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (NASDAQ: EDSA) CEO opts to receive 90% of salary in RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWjJUYXVRODJXaWZtVjZZWEJqRlVfelItZ1RCV2xQazVhVlh6MmszM0NtOW5yZFVkYVh5TndYUHZpcjVxVkU2SDl5c2VET002dTI1Q0dQUThPY1UwZFU0RlEzd3pKekpZa0ZLSWtvbHBLXzJqeHZkUEM4V1Nmb2ZHem1FX3g0M0Z1WlFjYng4NjR0T1pNOXZ2YWtLRkE2d0RLLTJNcDh3U3gxdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/edesa-biotech-reports-fiscal-2nd-203000211.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:30:00+00:00", "published_display": "14 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOWWVHSEV5UWkxNDN2NmJBMS1iZWlIQm9jWVNtS2hmajdmX0J0VVFjWmNtRUJrdDZoc3ZydnlRNHM4Z3lBZUVnNDR3S1hzVlM4Y0RiemJRUXlYd3pPTlRsSVc2dHBOQU9CSjVVdTEwRnAyMkNkdS15dXJIbTktYzNtbFhnc3gyaGc3dFh4WmpXWVhzLXhVTTdhcw?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOeDdNUlF4alQ1a05iQVYzenQtbmdxTzYzbktyOE50azV0MW9DZ0ctNFM3VkltLWZ4R3F3T0ZsOUpxX3JUNnZQOFR5UjNnOEJkOGVWRWFRS0VqY3BnUk5WMVZJMU9WYVMwRmpFOFNPaHR6THNXZDB3RENCeTl2aWlDVUZjZlFYeW1BTlplVUVoQWlfMFJnZEZzRVhMQ2xxeDkxREROLQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQNVp6bUhoMFhoQlNCSWVWUkk1emZHeHBZUlVSMWlFb18yTmZyMUVsSHNxME5zSlhmM2xPc3BhYzktd1dhVDhlZTVWdHEtN1NEOFBGc2JHaW9xYkZEbWFxY3lXTWJVMjFjQUxOTTY0UWJxSVdXQ3NsdnU2dk9uU0hLMVM0bHRhN1NKOEFVeGtTSklYd2J4U0N5OFFGSmxwUkNSdTJ4RGhSd3gxdFVOaExnSk1RamZybFBSOVVmM0tKRV91U3EwbzJqNzJ3QnI2SC1G?oc=5", "source_name": "Investorideas.com", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech stock surges on positive Phase 3 trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPaUN2OTd4RVNxTU9vY1k4dktwaGNNUmYxeWphMlUwNTZmQWZDNk8wWTZaNFNZMGdaM0pvSUluOWtmYlJkSi1yeVhzbGpPYk1xaTZrQlU1QkVMWEMtbTNKLVg4TnRuYlczdkltQS1QbWhaY0hjd01VMDNwTGRRbDRGOUlxVWdHNUc4a0hzNGQzZ0g2X3pLcmV4YlNuamN5Yk1GYjEyQnU3X0dybmRoYWhUN28wQ3QxUGZadXln?oc=5", "source_name": "Investing.com", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB1b3JEMFVhdzZtc1gwc3Bib2tpVi1wZ0IzRmZBdndJblI5dExJZFJQZGFMYWdnVzVPa3dxT25GN2lGcnk0NnBtYkFNdjB0ZUI2TTk0?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:54:38+00:00", "published_display": "25 Apr 2025 00:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "[EFFECT] Edesa Biotech, Inc. SEC Filing", "summary": "This article announces an EFFECT SEC filing for Edesa Biotech, Inc. (EDSA), indicating the effectiveness of an S-3 Shelf Registration Statement. The filing has a neutral impact and sentiment, and the notice of effectiveness specifies July 13, 2026, as the effective date. The arti", "url": "https://www.stocktitan.net/sec-filings/EDSA/effect-edesa-biotech-inc-sec-filing-dbec03d1d2d5.html", "source_name": "Stock Titan", "published_at": "2026-07-14T09:41:58", "published_display": "14 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) details $3.5M private placement and 729,241-share resale", "summary": "Edesa Biotech (EDSA) has registered 729,241 common shares for resale by existing investors who participated in a June 2026 private placement, raising approximately $3.5 million. The company itself will not receive any proceeds from these resales, as the original private placement", "url": "https://www.stocktitan.net/sec-filings/EDSA/424b3-edesa-biotech-inc-prospectus-filed-pursuant-to-rule-424-b-3-812a0759bd19.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:40:35", "published_display": "13 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDSA Stock Rallied Over 50% Today: What\u2019s Ahead For The Small-Cap Biotech?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOVVUyQnQ0RmZrdFVCUk9RYU55bUdHeURCVTR2ZjlmN1dfSkJvZi0tWkNyS3BZRWVmdU96RWRfd2R2V1NDV3JwamJKcy11aVQ5U1NnemhJTXJNRkdVcnVIZk8xdkhoblpXYVliZjIySWh6WjNFZGFTbjNtQy1qdXpWbXk1dGZKZlMtaUw5ZXNxdlVlbWdDdnpsWWFSbnFnUVhPcWV2d0Q2bUhscDlzUEtPV0JLdUNhV29QeEtQRTNkUFVnZ0g0SzU5RTg1amdHYmVoZW9DbQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-12T15:00:21+00:00", "published_display": "12 Jul 2026 15:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech(EDSA) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxQeTJ3TUs5Rlh4UlBLTXBaWk9fTThqV2ZDZWVscV9rMEhGMElVZU04WVo0UU9PN0FOR001TV9RS0hMdlBMUGlnYS00R1JvdDhIUmVzOENlM2VTbVlKOUZRejdCTkNrQ01ISEF1UlI2LU5ibjRDeHFGWFJZcUlDelBrWjdTTlBqaXRwNEtYTHpjTWRkREFvZFI1eGREdWlNYXVReE9OZGRhWXcxeUg5SEd6bV93aFlPSmF5ODJZZTNieFZwc3RmWENMOUU5aHNfS3pGc3N3SkpwSXRienlTU0pxMC1yTGpJZ2Zfb21BMlVsVHNPYXNyLWdfZTBNOXVxMURSaEJDcFNHM1NPNHBmTWtUSlRiM0RmOXlJVk9RbjZvbHMwMGd0djF1VVNGVQ?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T05:07:53+00:00", "published_display": "08 Jul 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Edesa Biotech, Inc. \u2013 NASDAQ:EDSA", "summary": "This article focuses on the enterprise value to EBIT forward for Edesa Biotech, Inc. (NASDAQ: EDSA). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics and market performance.", "url": "https://www.tradingview.com/symbols/NASDAQ-EDSA/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T09:11:10", "published_display": "06 Jul 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech | 4: Statement of changes in beneficial ownership of securities-Officer Nijhawan Pardeep", "summary": "This document is a Statement of Changes in Beneficial Ownership of Securities (Form 4) for Officer Nijhawan Pardeep at Edesa Biotech. It indicates a filing related to the beneficial ownership of securities, likely detailing transactions or holdings by the named officer.", "url": "https://www.moomoo.com/news/notice/306619730/edesa-biotech-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-07-05T01:09:30", "published_display": "05 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) CEO receives 3,378-share RSU grant", "summary": "Edesa Biotech's CEO, Pardeep Nijhawan, was granted 3,378 restricted share units (RSUs) which vested immediately under the company's 2019 Equity Incentive Compensation Plan. This grant increases his direct holdings to 888,062 common shares. The Form 4 filing also details his indir", "url": "https://www.stocktitan.net/sec-filings/EDSA/form-4-edesa-biotech-inc-insider-trading-activity-5eb05e4f930e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:30", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (NASDAQ: EDSA) registers 729,241 shares for resale", "summary": "Edesa Biotech Inc. (NASDAQ: EDSA) has filed an S-3 registration statement to allow for the resale of up to 729,241 common shares. These shares were issued in a recent private placement that closed on June 16, 2026, generating approximately $3.5 million for the company, but Edesa ", "url": "https://www.stocktitan.net/sec-filings/EDSA/s-3-edesa-biotech-inc-shelf-registration-statement-a4071fb6ecfb.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:40:30", "published_display": "02 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EDSA: Positive Exploratory Data in Patients with AKI", "summary": "Edesa Biotech, Inc. (EDSA) announced positive exploratory data for its drug paridiprubart (EB05) in patients with acute kidney injury (AKI) and acute respiratory distress syndrome (ARDS), showing a significant 32% relative reduction in 28-day mortality and a 23% relative reductio", "url": "https://scr.zacks.com/news/news-details/2026/EDSA-Positive-Exploratory-Data-in-Patients-with-AKI-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-07-02T16:40:30", "published_display": "02 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brookline Capital Initiates Edesa Biotech(EDSA.US) With Buy Rating, Announces Target Price $21", "summary": "Brookline Capital has initiated coverage on Edesa Biotech (EDSA.US) with a Buy rating. The firm has set a price target of $21 for Edesa Biotech's stock. This initiation and target price announcement suggest a positive outlook for the company from Brookline Capital.", "url": "https://www.moomoo.com/news/post/72210663/brookline-capital-initiates-edesa-biotech-edsaus-with-buy-rating-announces", "source_name": "Moomoo", "published_at": "2026-06-29T21:40:17", "published_display": "29 Jun 2026 21:40", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brookline initiates Edesa Biotech stock with buy on pipeline", "summary": "Brookline Capital Markets has initiated coverage on Edesa Biotech (NASDAQ: EDSA) with a buy rating and a price target of $21.00, citing the company's promising pipeline which includes EB06 for vitiligo and a Phase 3-ready asset, EB01, for allergic contact dermatitis. The firm als", "url": "https://www.investing.com/news/analyst-ratings/brookline-initiates-edesa-biotech-stock-with-buy-on-pipeline-93CH-4766205", "source_name": "Investing.com", "published_at": "2026-06-29T20:39:38", "published_display": "29 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech, Inc. Actuals & Estimates (NASDAQ:EDSA)", "summary": "This article provides an overview of Edesa Biotech, Inc. (EDSA) stock, including its current price, performance, analyst forecasts, and financial data. It highlights the company's market capitalization, upcoming earnings report date, and recent revenue and net income figures. The", "url": "https://www.tradingview.com/symbols/NASDAQ-EDSA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:41:45", "published_display": "26 Jun 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Edesa Biotech, Inc. \u2013 NASDAQ:EDSA", "summary": "This page provides financial information for Edesa Biotech, Inc. (NASDAQ: EDSA), specifically focusing on its Price to Book Forward metric. The content indicates that the market was closed at the time of viewing, with no trades executed for the company. The page is from TradingVi", "url": "https://www.tradingview.com/symbols/NASDAQ-EDSA/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T19:40:24", "published_display": "25 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Edesa Biotech, Inc. \u2013 NASDAQ:EDSA", "summary": "This article briefly mentions the \"Price to sales forward\" metric for Edesa Biotech, Inc. (NASDAQ: EDSA), indicating it's a financial data point available on TradingView. The page appears to be a financial overview or data display page for the company on the platform.", "url": "https://www.tradingview.com/symbols/NASDAQ-EDSA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:39:48", "published_display": "25 Jun 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO, Company Secretary & Director of Edesa Biotech Pardeep Nijhawan Buys 28% More Shares", "summary": "Pardeep Nijhawan, CEO of Edesa Biotech, recently purchased US$800k worth of company stock at an average price of US$5.21, increasing his holding by 28%. This was the largest insider purchase in the last year, with insiders being net buyers overall despite making previous investme", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edsa/edesa-biotech/news/ceo-company-secretary-director-of-edesa-biotech-pardeep-nijh", "source_name": "Simply Wall Street", "published_at": "2026-06-19T12:09:13", "published_display": "19 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) joint filing reports 5.4% stake by Millennium group", "summary": "A Schedule 13G filing reveals that a group of related entities, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, collectively hold a 5.4% beneficial ownership in Edesa Biotech (EDSA). This stake, a", "url": "https://www.stocktitan.net/sec-filings/EDSA/schedule-13g-edesa-biotech-inc-passive-investment-disclosure-5-2150c1c98f1d.html", "source_name": "Stock Titan", "published_at": "2026-06-18T20:40:37", "published_display": "18 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Inc (EDSA) Institutional Confidence", "summary": "The article analyzes the institutional confidence in Edesa Biotech Inc (EDSA), noting a current shareholding score of 3.00, placing it 193rd out of 388 in its industry. Institutional shareholding proportion increased by 52.45% quarter-over-quarter to 49.07%. Steven Cohen is ident", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edsa/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:53", "published_display": "18 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Inc (EDSA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Edesa Biotech Inc (EDSA), detailing its current risk score, beta value, and various volatility metrics. The company ranks 233 out of 388 in the Biotechnology & Medical Research industry with a risk assessment score of 2.19. Key metrics ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edsa/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T08:39:53", "published_display": "18 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Edesa Biotech Inc (EDSA), highlighting its current earnings forecast score, average analyst price target of $9.00, and a \"Buy\" trend based on 2 analysts. It also details the company's recent and expected EPS performance and compares i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edsa/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:10:50", "published_display": "18 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Inc (EDSA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Edesa Biotech Inc.'s (EDSA) dividend history and stock splits. It notes that the company has not distributed any dividends in the past five years and details a 7-for-1 reverse merger stock split that occurred on October 10, 2023. The article a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-edsa/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:10:50", "published_display": "17 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) CEO invests $799,995.50 in private share purchase", "summary": "Edesa Biotech's CEO, Pardeep Nijhawan, privately purchased 153,550 common shares at $5.21 each, totaling $799,995.50, increasing his direct holdings to 884,684 shares. This strategic investment, noted in a Form 4 SEC filing, signifies a significant commitment to the company. The ", "url": "https://www.stocktitan.net/sec-filings/EDSA/form-4-edesa-biotech-inc-insider-trading-activity-2333bb03c6d2.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:25", "published_display": "16 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nijhawan lifts Edesa Biotech (EDSA) beneficial ownership stake to 19.99%", "summary": "Dr. Pardeep Nijhawan has increased his beneficial ownership in Edesa Biotech, Inc. (EDSA) to 19.99% through various transactions including restricted stock unit grants, open-market purchases, and a private placement. This updated ownership of 2,210,022 common shares is detailed i", "url": "https://www.stocktitan.net/sec-filings/EDSA/schedule-13d-a-edesa-biotech-inc-amended-major-shareholder-report-0961c8bee2f4.html", "source_name": "Stock Titan", "published_at": "2026-06-16T21:09:25", "published_display": "16 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did EDSA Stock Rally More Than 70% Today?", "summary": "Edesa Biotech's stock surged over 70% after reporting positive late-stage study results for its experimental drug, paridiprubart, which showed a statistically significant reduction in mortality for Acute Respiratory Distress Syndrome (ARDS) patients. The company is now pursuing r", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-edsa-stock-rally-today/cZRwIqaR4Cs", "source_name": "Stocktwits", "published_at": "2026-06-14T04:09:41", "published_display": "14 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech, Inc. Announces $3.5 Million PIPE Financing to Advance Clinical Programs", "summary": "Edesa Biotech, Inc. has secured approximately $3.5 million through a private investment in public equity (PIPE) financing. This funding, involving the sale of common shares to investors and the CEO, is intended to advance the company's vitiligo program, support its drug candidate", "url": "https://www.quiverquant.com/news/Edesa+Biotech,+Inc.+Announces+$3.5+Million+PIPE+Financing+to+Advance+Clinical+Programs", "source_name": "Quiver Quantitative", "published_at": "2026-06-12T20:41:45", "published_display": "12 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Raises $3.5 Million in Private Placement, Issues 729,241 Shares", "summary": "Edesa Biotech has successfully raised $3.5 million through a private placement, issuing 729,241 common shares to various investors including its CEO, with prices set at $4.69 and $5.21 respectively. The company also entered a Registration Rights Agreement, committing to file resa", "url": "https://www.tradingview.com/news/tradingview:1084aa11122ab:0-edesa-biotech-raises-3-5-million-in-private-placement-issues-729-241-shares/", "source_name": "TradingView", "published_at": "2026-06-11T13:39:43", "published_display": "11 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors", "summary": "Edesa Biotech, Inc. announced a private placement (PIPE) financing expected to generate approximately $3.5 million in gross proceeds. The investment, which includes participation from Edesa's CEO and healthcare-focused investors, will fund the advancement of the company\u2019s vitilig", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310539/0/en/edesa-biotech-announces-3-5-million-private-placement-of-common-shares-led-by-ceo-and-healthcare-focused-investors.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T13:39:43", "published_display": "11 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (Nasdaq: EDSA) sets $3.5M PIPE led by CEO", "summary": "Edesa Biotech has announced a private placement (PIPE) financing expected to raise approximately $3.5 million. The company will sell 729,241 common shares, with its CEO purchasing shares at a slightly higher price than other investors, demonstrating insider participation. Proceed", "url": "https://www.stocktitan.net/sec-filings/EDSA/8-k-edesa-biotech-inc-reports-material-event-66d415f42a04.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:43", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO backs $3.5M raise to advance Edesa vitiligo work", "summary": "Edesa Biotech has announced a $3.5 million private placement of common shares, led by its CEO and healthcare-focused investors. The proceeds will be used to advance the company's vitiligo program and its drug candidate paridiprubart, as well as for general corporate purposes. The", "url": "https://www.stocktitan.net/news/EDSA/edesa-biotech-announces-3-5-million-private-placement-of-common-lkm85qgw68zw.html", "source_name": "Stock Titan", "published_at": "2026-06-11T13:39:43", "published_display": "11 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech, Inc. announced that it expects to receive $3.42014 million in funding", "summary": "Edesa Biotech, Inc. is set to receive $3.42014 million in funding through a private placement of 729,241 common shares at $4.69 per share. The transaction, expected to close on June 15, 2026, includes participation from the company's CEO and healthcare-focused investors. This fun", "url": "https://www.marketscreener.com/news/edesa-biotech-inc-announced-that-it-expects-to-receive-3-42014-million-in-funding-ce7f5cd8de81f22c", "source_name": "www.marketscreener.com", "published_at": "2026-06-10T15:09:18", "published_display": "10 Jun 2026 15:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Says Paridiprubart Linked to Lower Risk of Death in Acute Kidney Injury Patients", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/edesa-biotech-says-paridiprubart-linked-141240796.html", "source_name": "MT Newswires", "published_at": "2026-06-05T14:12:40+00:00", "published_display": "05 Jun 2026 14:12", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/edesa-biotech-reports-positive-exploratory-132000030.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T13:20:00+00:00", "published_display": "05 Jun 2026 13:20", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Early trial data hint at fewer deaths from acute kidney injury", "summary": "Edesa Biotech (Nasdaq: EDSA) reported positive exploratory data for its drug paridiprubart in 101 hospitalized patients with acute kidney injury (AKI) and respiratory distress. The data, drawn from prior Phase 2/3 ARDS studies, suggested a 32% relative reduction in 28-day mortali", "url": "https://www.stocktitan.net/news/EDSA/edesa-biotech-reports-positive-exploratory-data-for-paridiprubart-in-h5u9vmajkinn.html", "source_name": "Stock Titan", "published_at": "2026-06-05T13:11:06", "published_display": "05 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploratory AKI data show lower mortality with paridiprubart at Edesa (NASDAQ: EDSA)", "summary": "Edesa Biotech (NASDAQ: EDSA) reported exploratory subgroup data indicating that its anti-TLR4 antibody, paridiprubart, may reduce mortality and major adverse kidney events (MAKE30) in critically ill patients with acute kidney injury (AKI) and respiratory distress. Pooled analyses", "url": "https://www.stocktitan.net/sec-filings/EDSA/8-k-edesa-biotech-inc-reports-material-event-28b8257eecb7.html", "source_name": "Stock Titan", "published_at": "2026-06-05T13:11:06", "published_display": "05 Jun 2026 13:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/edesa-biotech-present-data-paridiprubart-131500125.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T13:15:00+00:00", "published_display": "19 May 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sirenia (EDSA) discloses 600,000-share, 7.2% stake in Edesa Biotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOQklXT1g0WUdnRDNjZ29qd29tVENWQzZaOXRTeWRzLVdpQnMwVWtRN0VPak1aa18tb3lWUkN6Y0dxQ2J1UG9tbmJsTmhncC1kUmVRUXVOUGZUaTdrY0FRM2U1aER2QkVFMWQ0QWJZVmlGeDJHM0VBb0JXZFFUQmtxZHNfamZoOUFweFItazhEZ1lhM2tJaWxLMXl2MnE2b2t6WFotY0RpeFBJM2w2eDg1bTB6aEJVSUZsVEhZS3FYTEJOdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (NASDAQ: EDSA) CEO opts to receive 90% of salary in RSUs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWjJUYXVRODJXaWZtVjZZWEJqRlVfelItZ1RCV2xQazVhVlh6MmszM0NtOW5yZFVkYVh5TndYUHZpcjVxVkU2SDl5c2VET002dTI1Q0dQUThPY1UwZFU0RlEzd3pKekpZa0ZLSWtvbHBLXzJqeHZkUEM4V1Nmb2ZHem1FX3g0M0Z1WlFjYng4NjR0T1pNOXZ2YWtLRkE2d0RLLTJNcDh3U3gxdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/edesa-biotech-reports-fiscal-2nd-203000211.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:30:00+00:00", "published_display": "14 May 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech Reaches US$68m Market Cap Benefiting Insider Stock Buying", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOWWVHSEV5UWkxNDN2NmJBMS1iZWlIQm9jWVNtS2hmajdmX0J0VVFjWmNtRUJrdDZoc3ZydnlRNHM4Z3lBZUVnNDR3S1hzVlM4Y0RiemJRUXlYd3pPTlRsSVc2dHBOQU9CSjVVdTEwRnAyMkNkdS15dXJIbTktYzNtbFhnc3gyaGc3dFh4WmpXWVhzLXhVTTdhcw?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOeDdNUlF4alQ1a05iQVYzenQtbmdxTzYzbktyOE50azV0MW9DZ0ctNFM3VkltLWZ4R3F3T0ZsOUpxX3JUNnZQOFR5UjNnOEJkOGVWRWFRS0VqY3BnUk5WMVZJMU9WYVMwRmpFOFNPaHR6THNXZDB3RENCeTl2aWlDVUZjZlFYeW1BTlplVUVoQWlfMFJnZEZzRVhMQ2xxeDkxREROLQ?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Stock Edesa Biotech (Nasdaq:EDSA) Gains on News of Additional Positive Results from Phase 3 Paridiprubart Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQNVp6bUhoMFhoQlNCSWVWUkk1emZHeHBZUlVSMWlFb18yTmZyMUVsSHNxME5zSlhmM2xPc3BhYzktd1dhVDhlZTVWdHEtN1NEOFBGc2JHaW9xYkZEbWFxY3lXTWJVMjFjQUxOTTY0UWJxSVdXQ3NsdnU2dk9uU0hLMVM0bHRhN1NKOEFVeGtTSklYd2J4U0N5OFFGSmxwUkNSdTJ4RGhSd3gxdFVOaExnSk1RamZybFBSOVVmM0tKRV91U3EwbzJqNzJ3QnI2SC1G?oc=5", "source_name": "Investorideas.com", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech stock surges on positive Phase 3 trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPaUN2OTd4RVNxTU9vY1k4dktwaGNNUmYxeWphMlUwNTZmQWZDNk8wWTZaNFNZMGdaM0pvSUluOWtmYlJkSi1yeVhzbGpPYk1xaTZrQlU1QkVMWEMtbTNKLVg4TnRuYlczdkltQS1QbWhaY0hjd01VMDNwTGRRbDRGOUlxVWdHNUc4a0hzNGQzZ0g2X3pLcmV4YlNuamN5Yk1GYjEyQnU3X0dybmRoYWhUN28wQ3QxUGZadXln?oc=5", "source_name": "Investing.com", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Edesa Biotech (EDSA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFB1b3JEMFVhdzZtc1gwc3Bib2tpVi1wZ0IzRmZBdndJblI5dExJZFJQZGFMYWdnVzVPa3dxT25GN2lGcnk0NnBtYkFNdjB0ZUI2TTk0?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:54:38+00:00", "published_display": "25 Apr 2025 00:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 51, "sentiment_summary": {"positive": 18, "negative": 2, "neutral": 31, "score": 59, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.75, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 7.01, "latest_week": "2026-07-10", "one_week_move": -6.5, "four_week_move": 20.9, "twelve_week_move": 18.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.473016, "market_dynamics_buy_signal": false, "relative_strength": 47.978563, "fair_value_gap": 80.1, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "negative", "expectation_probability": 36.4553, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.5% over one week, +20.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 70, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "Stocktwits", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 13}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.5% over one week, +20.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "[EFFECT] Edesa Biotech, Inc. SEC Filing"}], "updated_at": "2026-07-16T02:02:30.753181+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}